Shaping the next evolution of immuno-oncology

Mary Jane Hinrichs, Global Head of Early Development

Redefining the next chapter of cancer innovation

Working in early development, I have the privilege to see the next generation of therapeutic science take shape – and few areas are more compelling than immuno-oncology (I-O). From first data points in the lab to breakthroughs in the clinic, it is clear that we are entering a new era with the potential to deliver transformative outcomes for patients.

That progress reflects a deepening sophistication – not only in our understanding of the immune system and its interaction with cancer, but in how we respond to real-world challenges faced by healthcare professionals, patients and families. Despite significant I-O breakthroughs, patient responses remain variable and immune-related toxicities widespread, underscoring the need for more refined and targeted approaches.¹

From ‘releasing the brakes’ to targeted approaches

First-generation I-Os showed that releasing the brakes on immune cells can drive meaningful responses, but also exposed the limits of broad immune activation. These learnings are now shaping next-generation approaches that engage the immune system more precisely: targeting specific pathways and cell types for a more coordinated, tailored immune response.²

By coordinating the immune systems rapid front-line defenses and it’s more targeted, lasting response, these emerging therapies have the potential to deliver deeper anti-tumor activity while carefully managing safety.^2,3

It’s this promise that shapes how we work at Ipsen. Grounded in precision, selectivity and deep cancer biology insight, we are advancing a growing I-O pipeline, spanning solid tumors and blood cancers with T cell engagers, T cell activators together with targeted antibody-drug conjugate therapies. I am especially driven by how next generation I-O approaches has the potential to deliver better tolerated options to patients living with acute myeloid leukemia, where unmet need remains so high.

Looking ahead

The pace of progress in I-O is remarkable, but the measure of success isn’t scientific sophistication. It’s whether that precision reaches patients living with cancers like AML, where current options remain inadequate. The tools are becoming sharper. The question now is how fast we can close the gap.